Document ID: chunk:federal_register_of_legislation:F2024L01336:front:0:p4
Version: federal_register_of_legislation:F2024L01336
Segment Type: other
Provision Reference: 
Character Range: 9640–13235

trigeminal nerve, at the time of clinical onset or clinical worsening;
Note: Examples of a mass lesion that can compress, displace or infiltrate the trigeminal nerve include a benign or malignant neoplasm, haematoma, abscess, granuloma, amyloidoma, cyst or benign fibro-osseous lesion.
 1.       having cervical disc prolapse or cervical syringomyelia, involving the cervical spine at C4 or above, at the time of clinical onset or clinical worsening of trigeminal neuropathy;

          1.       having one of the following inflammatory connective tissue diseases:
                  1.           mixed connective tissue disease;
                  2.           Sjögren syndrome;
                  3.           systemic lupus erythematosus;
                  4.           systemic sclerosis (scleroderma);

         at the time of clinical onset or clinical worsening;
 1.        having sarcoidosis at the time of clinical onset or clinical worsening of trigeminal neuropathy;
 2.       having invasive bacterial or fungal paranasal sinusitis or viral meningoencephalitis, at the time of clinical onset or clinical worsening of trigeminal neuralgia;
 3.       having one of the following infections involving the affected trigeminal nerve, at the time of clinical onset or clinical worsening of trigeminal neuropathy:
         1.           abscess;
         2.           Lyme disease (Borrelia burgdorferi infection);
         3.           brainstem meningitis or encephalitis;
         4.           herpes simplex virus infection;
         5.           invasive bacterial or fungal sinusitis;
         6.            leprosy (Mycobacterium leprae infection);
         7.           odontogenic infection;
         8.           osteomyelitis;
         9.             suppurative otitis media;
 4.       having acute herpes zoster involving the affected trigeminal nerve, within the 6 months before clinical onset or clinical worsening of trigeminal neuropathy;
 5.       having multiple sclerosis at the time of clinical onset or clinical worsening;
 6.       having Charcot–Marie–Tooth disease at the time of clinical onset or clinical worsening of trigeminal neuralgia;
 7.       having a cerebrovascular accident (stroke) involving the brainstem within the 30 days before clinical onset or clinical worsening;
 8.       inhaling, ingesting or having cutaneous contact with trichloroethylene on at least 30 occasions, within the 6 months before clinical onset or clinical worsening of trigeminal neuropathy;
 9.       having an episode of acute intoxication, from inhaling, ingesting or having cutaneous contact with trichloroethylene, within the 30 days before clinical onset or clinical worsening of trigeminal neuropathy;
10.       inability to obtain appropriate clinical management for trigeminal neuralgia before clinical worsening of trigeminal neuralgia;
11.       inability to obtain appropriate clinical management for trigeminal neuropathy before clinical worsening of trigeminal neuropathy.
 1.            Relationship to service
        1.           The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.
        2.           The clinical worsening aspects of factors set out in section 9 apply only to material contribution to, or aggravation of, trigeminal neuralgia or trigeminal neuropathy where the person's trigeminal neuralgia or trigeminal neuropathy was suffered or contracted before or during (but did not arise out of) the person's relevant service.
 2.            Factors referring to an injury or